We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+31.06%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.34B
AUM Growth
+$386M
(+40%)
Cap. Flow
+$185M
Cap. Flow
% of AUM
13.81%
Top 10 Holdings %
Top 10 Hldgs %
66.32%
Holding
61
New
9
Increased
9
Reduced
28
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$48.6M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$40.7M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$24.8M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$22.5M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$19.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$25.1M |
| 2 |
KA
Kineta, Inc. Common Stock
KA
|
+$19.2M |
| 3 |
AnaptysBio
ANAB
|
+$16.6M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$14.2M |
| 5 |
Wave Life Sciences
WVE
|
+$7.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONSIW
51
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
| $15K | ﹤0.01% |
416,666
| – | – |
|
|
CLRBW
52
DELISTED
Cellectar Biosciences, Inc.
CLRBW
| $6K | ﹤0.01% |
52,999
| – | – |
|
53
Ardelyx
ARDX
$1.21B
| – | – |
-572,738
| Closed | -$3.78M |
|
|
BLUE
54
DELISTED
bluebird bio
BLUE
| – | – |
-6,176
| Closed | -$14.2M |
|
|
MRSN
55
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-11,822
| Closed | -$4.86M |
|
56
Outlook Therapeutics
OTLK
$187M
| – | – |
-191
| Closed | -$40K |
|
57
Ovid Therapeutics
OVID
$489M
| – | – |
-223,972
| Closed | -$2.21M |
|
|
58
Wave Life Sciences
WVE
$1.18B
| – | – |
-202,079
| Closed | -$7.09M |
|
|
SYRS
59
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-29,630
| Closed | -$2.88M |
|
|
KA
60
DELISTED
Kineta, Inc. Common Stock
KA
| – | – |
-23,571
| Closed | -$19.2M |
|
|
JUNO
61
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – |
-550,000
| Closed | -$25.1M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, Cormorant Asset Management held 61 positions worth $1.34B, up 40% from $955M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Cormorant Asset Management deployed $185M of net new capital in Q1 2018, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Sage Therapeutics: 239,619 shares worth $38.6M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier.
On the sell side, the largest reduction was AnaptysBio, an estimated $16.6M trimmed.
- Cormorant Asset Management's largest Q1 2018 buy was Sage Therapeutics: 239,619 shares worth $38.6M.
- Cormorant Asset Management added most to Nektar Therapeutics in Q1 2018, an estimated $48.6M increase.
- Cormorant Asset Management's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $16.6M.
- Cormorant Asset Management fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $25.1M.
- Cormorant Asset Management's ten largest holdings make up 66% of its $1.34B portfolio in Q1 2018.
- Cormorant Asset Management opened 9 new positions and closed 9 in Q1 2018.
- Cormorant Asset Management's portfolio value rose 40% quarter-over-quarter to $1.34B.
Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.